Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences: Gilead's casdatifan option expires; Arcus keeps full rights

Positive Impact 4 of 5 product/contract Written later

Gilead Sciences' time-limited exclusive option to casdatifan expired without exercise, so Gilead has no future rights to the program and Arcus retains full global development and commercial rights, subject to Taiho's option for Japan and certain other Asian countries (excluding China). Arcus also reported preliminary cash, cash equivalents and marketable securities of approximately $992 million as of December 31, 2024, which remains unaudited and subject to closing procedures.

Key points

  • Gilead's casdatifan option expired without exercise, as announced February 18, 2025; Gilead has no future rights to casdatifan.
  • Taiho Pharmaceutical's option right covers its territory, limited to Japan and certain other Asian countries (excluding China).
  • Preliminary cash, cash equivalents and marketable securities were approximately $992 million as of December 31, 2024, unaudited and may change.
  • ARC-20 data reported February 15, 2025 (data cut-off January 3, 2025): confirmed ORR of 33% (9) in the 100mg QD cohort of 27 patients.

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECFeb 18, 2025, 6:44 AM ET
Accession number0001193125-25-028110

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 18, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.